Overcoming Acquired PD-1 Resistance in NSCLC: Tislelizumab + Sitravatinib + Docetaxel - OncoDaily Phase II study explores tislelizumab, sitravatinib, and docetaxel to overcome acquired PD-1 resistance in advanced NSCLC with immune remodeling signals.

Overcoming Acquired PD-1 Resistance in NSCLC: Tislelizumab + Sitravatinib + Docetaxel

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer #Tislelizumab #Sitravatinib #Docetaxel

A Phase II Study of Sitravatinib Combined With Tislelizumab Plus Docetaxel for Acquired Resistance to PD‐(L)1 in Patients With Advanced/Metastatic Non‐Small Cell Lung Cancer Over 60% of NSCLC patients treated with immune checkpoint inhibitors (ICIs) develop acquired resistance (AR). This study demonstrates that combining tislelizumab, sitravatinib, and docetaxel achieves...

#Article in #MedComm
A Phase II Study of #Sitravatinib Combined With #Tislelizumab Plus Docetaxel for Acquired #Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer doi.org/10.1002/mco2...

#AcquiredResistance #Tcell #immunotherapy #PSI #TCR